NAD Reviews Hims & Hers Hair Loss Product Claims

The National Programs’ National Advertising Division (NAD) reviewed advertising challenged by Kenvue Inc. for four Hims & Hers compounded hair-loss products: Hims Topical Finasteride & Minoxidil Spray, Hims Topical Finasteride & Minoxidil Serum, Hers Postmenopausal Hair Loss Spray and Hers Hair Blends Postmeno Serum.

NAD recommended removing the unsupported “doctor trusted” language from a comparative efficacy claim about combining finasteride and minoxidil. It recommended that Hims & Hers:

• Qualify “doctor-trusted ingredients” claims with the underlying dermatologist survey results and the applicable ingredients, combinations and patient populations.
• Discontinue the claim that Hims Hair Hybrids contain “dermatologist-recommended prescription ingredients.”
• Revise safety and side-effect claims to distinguish evidence about topical finasteride generally from evidence concerning the specific compounded products advertised.
• Identify relevant evidence limitations and avoid suggesting that local scalp reactions are the only material risks.
• Clearly disclose material non-local risks, where appropriate, and place safety disclosures clearly and conspicuously near the claims they qualify.

The decision reinforces that health and pharmaceutical marketers ensure claims about efficacy, expert support, safety and side effects are supported by evidence and clearly communicate important limitations and risks to consumers, said NAD.

Read the full letter here.

Upcoming Meeting

The BBB National Programs National Advertising Division Annual Conference will be held Sept. 28-29 at The Conrad New York Downtown in New York City, as reported in Happi.

Hims & Hers Expands Into GLP-1s

Besides hair loss products, the online wellness platform is also growing its portfolio to include GLP-1 products. Read about it here.